FDA has accepted Seattle Genetics’ new drug application for its investigational medicine tucatinib for Priority Review.
The same House appropriators who, with bipartisan resolve, oversaw years of dramatic funding increases for NIH expressed equally bipartisan misgivings about President Joe Biden’s proposal to boost funding for the Advanced Research Projects Agency for Health while giving NIH a meager raise—and cutting funds for NCI.
